Classical psychedelic drugs show promise as a treatment for major depressive disorder and related psychiatric disorders. This therapeutic efficacy stems from long-lasting psychedelic-induced neuroplasticity onto prefrontal cortical neurons and is thought to require the postsynaptic expression of serotonin 2A receptors (5-HT_2AR). However, other cortical regions such as the granular...
The rapid expansion of psychedelic research has opened significant pathways of opportunity in treating mental health disorders. Participants in recent clinical trials consistently report mystical-type experiences during dosing sessions, and some scholars posit that such experiences themselves help mediate clinical improvements in depression, PTSD, anxiety, and substance use disorders. These...
Background: Major depressive disorder (MDD) is a highly prevalent and disabling psychiatric condition associated with substantial clinical, social, and economic burden [1,2]. Despite the availability of conventional antidepressants, their limited effectiveness, delayed onset of action, and high relapse rates have renewed interest in innovative therapeutic approaches [3,4,5]. Psilocybin-assisted...
In Sufism, fana’ refers to the dissolution of the self, the annihilation of the ego as one transcends individuality. While traditionally a spiritual concept, fana’ also offers a powerful humanistic metaphor for psychological transformation. In both the poem and accompanying photograph, fana’ explores the themes of ego death, grief, and the reshaping of identity: processes central to psychiatric...
Psychedelic-assisted therapies (PATs) can produce rapid and sustained antidepressant effects, yet variability in response remains substantial. Identifying predictors and moderators is essential for optimising patient selection, preparation, and delivery. To map and synthesise the evidence on the predictors of antidepressant response to classic/serotonergic psychedelics administered with...
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics as breakthrough therapies for mental disorders. Psychedelics can influence cognitive and emotional processes, showing solid therapeutic potential, particularly in treatment-resistant psychiatric disorders. Amongst the most promising compounds,...
A mystical experience typically includes feelings of unity and heightened connection, an enhanced positive mood, the sensation of transcending time and space, and ineffability. They are understood as both common, significantly impactful for individuals who have them and can occur under several circumstances. The rise of psychedelic-assisted psychotherapy has seen an increased understanding of...
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
Abstract Background and aims An increasing number of individuals seek psychedelics for mental illness, and when seeking psychotherapy in the aftermath, psychotherapists have an ethical duty to attempt to reduce harms and maximise benefits from these experiences. The Internal Family Systems (IFS) model of therapy is sometimes chosen as the therapeutic approach in psychedelic-assisted...
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic stress disorder. With rising global mental health burdens and the limitations of existing pharmacological treatments, ketamine's novel mechanism of action provides a potential alternative for individuals who have not responded to traditional therapies....